Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartinez-Hernaez, Angel-
dc.contributor.authorPié Balaguer, Asunción-
dc.contributor.authorSerrano-Miguel, Mercedes-
dc.contributor.authorMorales Sáez, Nicolás-
dc.contributor.authorGarcía-Santesmases Fernández, Andrea-
dc.contributor.authorBekele, Deborah-
dc.contributor.authorAlegre Agís, Elisa-
dc.identifier.citationMartínez-Hernáez, A. [Ángel], Pié Balaguer, A. [Asunción], Serrano-Miguel, M. [Mercedes], Morales-Sáez, N. [Nicolás], García-Santesmases Fernández, A. [Andrea], Bekele, D. [Deborah] & Alegre-Agís, E. [Elisa](2020). The collaborative management of antipsychotic medication and its obstacles: A qualitative study. Social Science & Medicine, 247(), 1-9. doi: 10.1016/j.socscimed.2020.112811-
dc.description.abstractAntipsychotic medication is the primary treatment for psychotic conditions such as schizophrenia and schizoaffective disorders; nevertheless, its administration is not free from conflicts. Despite taking their medication regularly, 25–50% of patients report no benefits or perceive this type of treatment as an imposition. Following in the footsteps of a previous initiative in Quebec (Canada), the Gestion Autonome de la Médication en Santé Mentale (GAM), this article ethnographically analyses the main obstacles to the collaborative management of antipsychotics in Catalonia (Spain) as a previous step for the implementation of this initiative in the Catalan mental healthcare network. We conducted in-depth interviews with patients (38), family caregivers (18) and mental health professionals (19), as well as ten focus groups, in two public mental health services, and patients’ and caregivers’ associations. Data were collected between February and December 2018. We detected three main obstacles to collaboration among participants. First, different understanding of the patient’s distress, either as deriving from the symptoms of the disorder (professionals) or the adverse effects of the medication (patients). Second, differences in the definition of (un)awareness of the disorder. Whereas professionals associated disorder awareness with treatment compliance, caregivers understood it as synonymous with self-care, and among patients “awareness of suffering” emerged as a comprehensive category of a set of discomforts (i.e., symptoms, adverse effects of medication, previous admissions, stigma). Third, discordant expectations regarding clinical communication that can be condensed in the differences in meaning between the Spanish words “trato” and “tratamiento”, where the first denotes having a pleasant manner and agreement, and the second handling and management. We conclude that these three obstacles pave the way for coercive practices and promote patients’ de-subjectivation, named here as the “total patient” effect. This study is the first GAM initiative in Europe.en
dc.relation.ispartofSocial Science & Medicine, 2020, 247-
dc.rightsCC BY-NC-ND-
dc.subjectantipsychotic medicationen
dc.subjectcollaborative management of medicationen
dc.subjecttherapeutic allianceen
dc.subjectmental healthen
dc.subjectqualitative researchen
dc.titleThe collaborative management of antipsychotic medication and its obstacles: A qualitative studyca
Appears in Collections:Articles cientÍfics

Files in This Item:
File Description SizeFormat 
Martinez_SSM_Collaborative.pdf377,69 kBAdobe PDFThumbnail
View statistics

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.